TY  - JOUR
AU  - Dixon, SC
AU  - Nagle, CM
AU  - Wentzensen, N
AU  - Trabert, B
AU  - Beeghly-Fadiel, A
AU  - Schildkraut, JM
AU  - Moysich, KB
AU  - deFazio, A
AU  - Australian Ovarian Cancer Study Group
AU  - Risch, HA
AU  - Rossing, MA
AU  - Doherty, JA
AU  - Wicklund, KG
AU  - Goodman, MT
AU  - Modugno, F
AU  - Ness, RB
AU  - Edwards, RP
AU  - Jensen, A
AU  - Kjær, SK
AU  - Høgdall, E
AU  - Berchuck, A
AU  - Cramer, DW
AU  - Terry, KL
AU  - Poole, EM
AU  - Bandera, EV
AU  - Paddock, LE
AU  - Anton-Culver, H
AU  - Ziogas, A
AU  - Menon, U
AU  - Gayther, SA
AU  - Ramus, SJ
AU  - Gentry-Maharaj, A
AU  - Pearce, CL
AU  - Wu, AH
AU  - Pike, MC
AU  - Webb, PM
Y2  - 2020/12/17
Y1  - 2017/04/25
SN  - 0007-0920
UR  - http://hdl.handle.net/11343/254856
AB  - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited. METHODS: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths). RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)). CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.
LA  - eng
PB  - Springer Science and Business Media LLC
T1  - Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
DO  - 10.1038/bjc.2017.68
IS  - British Journal of Cancer
VL  - 116
IS  - 9
SP  - 1223-1228
L1  - /bitstream/handle/11343/254856/PMC5418444.pdf?sequence=1&isAllowed=y
ER  -